PURPOSE: The unilateral 6-hydroxydopamine (6-OHDA) lesion rat model is a well-known acute model for Parkinson's disease (PD). Its validity has been supported by invasive histology, behavioral studies and electrophysiology. Here, we have characterized this model in vivo by multitracer imaging [glucose metabolism and dopamine transporter (DAT)] in relation to behavioral and histological parameters. METHODS: Eighteen female adult Wistar rats (eight 6-OHDA-lesioned, ten controls) were investigated using multitracer [(18)F]-fluoro-2-deoxy-D: -glucose (FDG) and [(18)F]-FECT {2'-[(18)F]-fluoroethyl-(1R-2-exo-3-exe)-8-methyl-3-(4-chlorophenyl)-8-azabicyclo(3.2.1)-octane-2-carboxylate} small animal positron emission tomography (PET). Relative glucose metabolism and parametric DAT binding images were anatomically standardized to Paxinos space and analyzed on a voxel-basis using SPM2: , supplemented by a template-based predefined volumes-of-interest approach. Behavior was characterized by the limb-use asymmetry test; dopaminergic innervation was validated by in vitro tyrosine hydroxylase staining. RESULTS: In the 6-OHDA model, significant glucose hypometabolism is present in the ipsilateral sensory-motor cortex (-6.3%; p = 4 x 10(-6)). DAT binding was severely decreased in the ipsilateral caudate-putamen, nucleus accumbens and substantia nigra (all p < 5 x 10(-9)), as confirmed by the behavioral and histological outcomes. Correlation analysis revealed a positive relationship between the degree of DAT impairment and the change in glucose metabolism in the ipsilateral hippocampus (p = 3 x 10(-5)), while cerebellar glucose metabolism was inversely correlated to the level of DAT impairment (p < 3 x 10(-4)). CONCLUSIONS: In vivo cerebral mapping of 6-OHDA-lesioned rats using [(18)F]-FDG and [(18)F]-FECT small animal PET shows molecular-functional correspondence to the cortico-subcortical network impairments observed in PD patients. This provides a further molecular validation supporting the validity of the 6-OHDA lesion model to mimic multiple aspects of human PD.
PURPOSE: The unilateral 6-hydroxydopamine (6-OHDA) lesion rat model is a well-known acute model for Parkinson's disease (PD). Its validity has been supported by invasive histology, behavioral studies and electrophysiology. Here, we have characterized this model in vivo by multitracer imaging [glucose metabolism and dopamine transporter (DAT)] in relation to behavioral and histological parameters. METHODS: Eighteen female adult Wistar rats (eight 6-OHDA-lesioned, ten controls) were investigated using multitracer [(18)F]-fluoro-2-deoxy-D: -glucose (FDG) and [(18)F]-FECT {2'-[(18)F]-fluoroethyl-(1R-2-exo-3-exe)-8-methyl-3-(4-chlorophenyl)-8-azabicyclo(3.2.1)-octane-2-carboxylate} small animal positron emission tomography (PET). Relative glucose metabolism and parametric DAT binding images were anatomically standardized to Paxinos space and analyzed on a voxel-basis using SPM2: , supplemented by a template-based predefined volumes-of-interest approach. Behavior was characterized by the limb-use asymmetry test; dopaminergic innervation was validated by in vitro tyrosine hydroxylase staining. RESULTS: In the 6-OHDA model, significant glucose hypometabolism is present in the ipsilateral sensory-motor cortex (-6.3%; p = 4 x 10(-6)). DAT binding was severely decreased in the ipsilateral caudate-putamen, nucleus accumbens and substantia nigra (all p < 5 x 10(-9)), as confirmed by the behavioral and histological outcomes. Correlation analysis revealed a positive relationship between the degree of DAT impairment and the change in glucose metabolism in the ipsilateral hippocampus (p = 3 x 10(-5)), while cerebellar glucose metabolism was inversely correlated to the level of DAT impairment (p < 3 x 10(-4)). CONCLUSIONS: In vivo cerebral mapping of 6-OHDA-lesioned rats using [(18)F]-FDG and [(18)F]-FECT small animal PET shows molecular-functional correspondence to the cortico-subcortical network impairments observed in PDpatients. This provides a further molecular validation supporting the validity of the 6-OHDA lesion model to mimic multiple aspects of humanPD.
Authors: G Berding; P Odin; D J Brooks; G Nikkhah; C Matthies; T Peschel; M Shing; H Kolbe; J van Den Hoff; H Fricke; R Dengler; M Samii; W H Knapp Journal: Mov Disord Date: 2001-11 Impact factor: 10.338
Authors: Petra Schweinhardt; Peter Fransson; Lars Olson; Christian Spenger; Jesper L R Andersson Journal: J Neurosci Methods Date: 2003-10-30 Impact factor: 2.390
Authors: Elena Prieto; María Collantes; Mercedes Delgado; Carlos Juri; Luis García-García; Francisco Molinet; María E Fernández-Valle; Miguel A Pozo; Belén Gago; Josep M Martí-Climent; José A Obeso; Iván Peñuelas Journal: Eur J Nucl Med Mol Imaging Date: 2011-08-27 Impact factor: 9.236
Authors: V Berti; C Polito; P Borghammer; S Ramat; L Mosconi; E Vanzi; M T De Cristofaro; M De Leon; S Sorbi; A Pupi Journal: Q J Nucl Med Mol Imaging Date: 2012-06 Impact factor: 2.346
Authors: Matthew D Silva; Charles Glaus; Jacob Y Hesterman; Jack Hoppin; Geraldine Hill Della Puppa; Timothy Kazules; Kelly M Orcutt; Mary Germino; David Immke; Silke Miller Journal: Am J Nucl Med Mol Imaging Date: 2013-03-08
Authors: Sarah Ann R Anderson; Michael Michaelides; Parisa Zarnegar; Yanhua Ren; Pernilla Fagergren; Panayotis K Thanos; Gene-Jack Wang; Michael Bannon; John F Neumaier; Eva Keller; Nora D Volkow; Yasmin L Hurd Journal: J Clin Invest Date: 2013-11-15 Impact factor: 14.808
Authors: Nicolaas I Bohnen; Satyanarayana Gedela; Priyantha Herath; Gregory M Constantine; Robert Y Moore Journal: Neurosci Lett Date: 2008-09-30 Impact factor: 3.046